Inventor · disambiguated record
Christophe Queva
Also filed as: QUEVA CHRISTOPHE · QUÉVA CHRISTOPHE
8 granted patents·19 pending applications·525 citations·filing 2006–2024
88Inventor score
Top patents by PatentIndex Score
27 records- 0195US9493565B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2014·Granted Nov 15, 2016·50 cites·8 claims
- 0295US8779108B2Targeted binding agents against B7-H1QUEVA CHRISTOPHE·Filed 2010·Granted Jul 15, 2014·452 cites·31 claims
- 0390US12208126B2Oncolytic viral vectors and uses thereofVIROGIN BIOTECH CANADA LTD·Filed 2023·Granted Jan 28, 2025·1 cites·23 claims
- 0490US10400039B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2016·Granted Sep 3, 2019·8 cites·8 claims
- 0589US10329349B2Anti-TIGIT antibodiesITEOS THERAPEUTICS SA·Filed 2018·Granted Jun 25, 2019·10 cites·26 claims
- 0685US11439705B2Anti-TIGIT antibodiesiTeos Belgium SA·Filed 2019·Granted Sep 13, 2022·3 cites·15 claims
- 0780US2024366518A1Compounds, compositions, and methods of using thereofELEVATEBIO TECH INC·Filed 2024·Application pending·0 cites
- 0880US2023235062A1Targeted binding agents against b7-h1MEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 0974US2023181731A1Anti-TIGIT AntibodiesiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 1073US2023190931A1Anti-TIGIT AntibodiesiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 1172US11612625B2Oncolytic viral vectors and uses thereofONCORUS INC·Filed 2018·Granted Mar 28, 2023·1 cites·26 claims
- 1271US2024173267A1Compounds, compositions, and methods of using thereofONCORUS INC·Filed 2022·Application pending·0 cites
- 1367US11518809B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2019·Granted Dec 6, 2022·0 cites·11 claims
- 1462US2015148345A1Therapies for treating myeloproliferative disordersGILEAD SCIENCES INC·Filed 2014·Application pending·0 cites
- 1562US2020407445A1Anti-tigit antibodiesITEOS THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 1661US2024390439A1Compositions and methods of seneca valley virus (svv) related cancer therapyELEVATEBIO TECH INC·Filed 2024·Application pending·0 cites
- 1758US2025049867A1Engineered oncolytic herpesvirusesVIROGIN BIOTECH CANADA LTD·Filed 2022·Application pending·0 cites
- 1854US2024115636A1Encapsulated rna polynucleotides and methods of useELEVATEBIO TECH INC·Filed 2022·Application pending·0 cites
- 1952US2007014720A1Antibodies directed to CD20 and uses thereofGAZIT-BORNSTEIN GADI·Filed 2006·Application pending·0 cites
- 2051US2016279135A1Therapies for treating myeloproliferative disordersGILEAD SCIENCES INC·Filed 2016·Application pending·0 cites
- 2151US2022380735A1Dual viruses and dual oncolytic viruses and methods of treatmentONCORUS INC·Filed 2020·Application pending·0 cites
- 2250US2022117902A1Encapsulated rna polynucleotides and methods of useONCORUS INC·Filed 2020·Application pending·0 cites
- 2350US2011129412A1Antibodies Directed to CD20 and Uses ThereofASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 2448US2023227577A1Anti-dll3 antibodies and methods of useONCORUS INC·Filed 2021·Application pending·0 cites
- 2538US2018353512A1Combination therapies for treating b-cell malignanciesGILEAD SCIENCES INC·Filed 2016·Application pending·0 cites
- 2637US2018207164A1Combination therapies for treating cancersGILEAD SCIENCES INC·Filed 2016·Application pending·0 cites
- 2728US2016331754A1Therapies for treating cancersGILEAD SCIENCES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christophe Queva files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →